Comparison of methods for the assessment of HIV-1 susceptibility to broadly neutralizing antibodies
Broadly neutralizing antibodies (bNAbs) are being developed for the prevention, treatment, and cure of HIV-1. The efficacy of a bNAb is dependent upon the susceptibility of an individual’s virus to the administered bNAb, which can be assessed phenotypically or genotypically. Both methods require cut-offs for susceptibility classification; however, clinical cut-offs for bNAb susceptibility have not been established. In this study, we assessed susceptibility to the two HIV-1 bNAbs 3BNC117 and 10–1074 among 59 newly diagnosed people living with HIV-1 using one phenotypic and four genotypic susceptibility assessment methods. We show that the methods employed and cut-offs assigned can greatly affect the susceptibility prediction. By evaluating the decay in plasma viral load for participants receiving 3BNC117 at ART initiation, clinically relevant cut-offs for susceptibility were identified using an exploratory approach, and application of these cut-offs resulted in 68%–76% of the viruses being correctly classified. No clinical data were available to set cut-offs for susceptibility to 10-1074. Instead, the methods were compared, and consensus-derived cut-offs were set, which resulted in concordant susceptibility assessments for 84% of the participants. In conclusion, our study underlines the importance of the chosen method and cut-off when assessing an individual’s virus susceptibility to HIV-1 bNAbs. Furthermore, we propose cut-offs for bNAb susceptibility to guide the design of future clinical trials.
Authors
- Jacqueline D. Reeves
- Maibritt Mardahl (ORCID: https://orcid.org/0000-0002-4581-7335)
- Martin Tolstrup (ORCID: https://orcid.org/0000-0001-7020-5173)
- Rolf Kaiser
- Martin Pirkl (ORCID: https://orcid.org/0000-0002-6986-0813)
- Víctor Ramos (ORCID: https://orcid.org/0000-0001-7353-3420)
- Henrik Støvring (ORCID: https://orcid.org/0000-0002-5821-2351)
- Christos J. Petropoulos (ORCID: https://orcid.org/0000-0001-5496-8090)
- Ole Schmeltz Søgaard (ORCID: https://orcid.org/0000-0001-9107-2023)
- Jesper Damsgaard Gunst (ORCID: https://orcid.org/0000-0002-3787-0259)
- Marie Høst Pahus (ORCID: https://orcid.org/0000-0003-0776-3847)
Institutions
- University of Cologne (DE)
- Aarhus University (DK)
- LabCorp (United States) (US)
- Aarhus University Hospital (DK)
- University Hospital Cologne (DE)
- Rockefeller University (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/fimmu.2026.1911783
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00